In Q4, Germany's lorazepam prices rose initially due to strong pharmaceutical demand but declined by December as inquiries waned. Sufficient supplies and reduced orders to avoid stockpiling led to a downturn. Surplus inventory and cautious trading weakened the market, ending the quarter on a subdued note. https://www.imarcgroup.com/lorazepam-pricing-report